Expression of SIRT1–7 mRNA in Patients with Middle Ear Cholesteatoma
7 affiliations
- 1Department of Otorhinolaryngology—Head & Neck Surgery, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul 02447, Republic of Korea
- 2Department of Otorhinolaryngology—Head and Neck Surgery, College of Medicine, Kyung Hee University Medical Center, Kyung Hee University, Seoul 02447, Republic of Korea
- 3Department of Food & Nutrition, College of Human Ecology, Kyung Hee University, Seoul 02447, Republic of Korea
- 4Clinical Research Institute, Kyung Hee University Medical Center, Seoul 02447, Republic of Korea
- 5Department of Medicine, College of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
- 6Department of History, Kyung Hee University, Seoul 02447, Republic of Korea
- 7Department of Biochemistry and Molecular Biology, College of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
Abstract
Background: Middle ear cholesteatoma is a locally destructive lesion that can cause severe complications and cannot be effectively managed with medical treatment alone. Although sirtuins are crucial epigenetic regulators of cellular metabolism, oxidative stress, and inflammatory responses, their specific roles in middle ear cholesteatoma remain unexplored. This study aimed to investigate the expression profiles of sirtuins and their association with the pathogenesis and clinical characteristics of cholesteatoma. Methods: The relative mRNA expression levels of seven sirtuin isoforms (SIRT1–7) were evaluated using quantitative real-time PCR in cholesteatoma tissues and matched postauricular skin controls obtained from 60 patients undergoing cholesteatoma surgery. Expression differences were analyzed according to tissue type, patient sex, and frequency of surgery (initial versus revision). Results: Clinically, otorrhea was observed in 58.3% of the patients, whereas the bacterial culture positivity rate was 16.7%. Conductive hearing loss was the predominant audiologic configuration. SIRT1–7 mRNA expression was detected in all cholesteatoma tissues, with SIRT1 exhibiting the highest relative expression, followed by SIRT4, SIRT3, SIRT6, SIRT7, SIRT5, and SIRT2. Notably, only the expression of SIRT7 was significantly downregulated in cholesteatoma tissues compared to postauricular skin controls (p = 0.002). No significant differences in SIRT1–7 expression were observed according to patient sex or history of revision surgery (p > 0.05). Conclusions: The distinct expression profiles of SIRT1–7 indicate their potential involvement in the pathogenesis of middle ear cholesteatoma. Although SIRT7 mRNA expression was lower in cholesteatoma tissue than in postauricular skin, this exploratory finding requires validation using tissue-appropriate controls and functional studies.
Related
- Baseline monocyte GIP receptor mRNA expression is associated with reductions in body weight and FIB-4 index after switching to tirzepatide in patients with type 2 diabetes.
- Exploring the potential of mRNA vaccines in combatting communicable and non-communicable diseases in low-income and lower-middle-income countries
- Pterostilbene attenuates VCD-induced ovarian damage through modulation of oxidative stress, inflammation, apoptosis, and SIRT1/FOXO3a gene expression
- Changes in Spontaneous and LPS-induced ex vivo Cytokine Production and mRNA expression in Male and Female Athletes Following Prolonged Exhaustive Exercise
- Developability engineering of scFvs enables robust CAR function under transient mRNA expression
BibTeX
@article{doo2026expression,
title = {{Expression of SIRT1–7 mRNA in Patients with Middle Ear Cholesteatoma}},
author = {Jeon Gang Doo and Jae Min Lee and Minsuh Park and Hye Ok Kim and Minji Choi and Yoo Jin Cha and In Uk Kang and Sung Soo Kim and Seung Geun Yeo},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15208195},
url = {https://www.mdpi.com/2077-0383/15/20/8195},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Expression of SIRT1–7 mRNA in Patients with Middle Ear Cholesteatoma
AU - Jeon Gang Doo
AU - Jae Min Lee
AU - Minsuh Park
AU - Hye Ok Kim
AU - Minji Choi
AU - Yoo Jin Cha
AU - In Uk Kang
AU - Sung Soo Kim
AU - Seung Geun Yeo
PY - 2026
DA - 2026/10/01
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15208195
UR - https://www.mdpi.com/2077-0383/15/20/8195
AB - Background: Middle ear cholesteatoma is a locally destructive lesion that can cause severe complications and cannot be effectively managed with medical treatment alone. Although sirtuins are crucial epigenetic regulators of cellular metabolism, oxidative stress, and inflammatory responses, their specific roles in middle ear cholesteatoma remain unexplored. This study aimed to investigate the expression profiles of sirtuins and their association with the pathogenesis and clinical characteristics of cholesteatoma. Methods: The relative mRNA expression levels of seven sirtuin isoforms (SIRT1–7) were evaluated using quantitative real-time PCR in cholesteatoma tissues and matched postauricular skin controls obtained from 60 patients undergoing cholesteatoma surgery. Expression differences were analyzed according to tissue type, patient sex, and frequency of surgery (initial versus revision). Results: Clinically, otorrhea was observed in 58.3% of the patients, whereas the bacterial culture positivity rate was 16.7%. Conductive hearing loss was the predominant audiologic configuration. SIRT1–7 mRNA expression was detected in all cholesteatoma tissues, with SIRT1 exhibiting the highest relative expression, followed by SIRT4, SIRT3, SIRT6, SIRT7, SIRT5, and SIRT2. Notably, only the expression of SIRT7 was significantly downregulated in cholesteatoma tissues compared to postauricular skin controls (p = 0.002). No significant differences in SIRT1–7 expression were observed according to patient sex or history of revision surgery (p > 0.05). Conclusions: The distinct expression profiles of SIRT1–7 indicate their potential involvement in the pathogenesis of middle ear cholesteatoma. Although SIRT7 mRNA expression was lower in cholesteatoma tissue than in postauricular skin, this exploratory finding requires validation using tissue-appropriate controls and functional studies.
SN - 2077-0383
ER -